| Methods |
4‐week single‐blind placebo run‐in; inclusion criteria= supine DBP 95‐114 mm Hg after run‐in; 12‐week double‐blind treatment; 293 patients included in safety analysis; 260 patients included in efficacy analyses |
| Participants |
Perindopril 2 mg: n=62(39 males,23 females); mean age=51(16) years; baseline SBP/DBP not reported for all 62 patients;
Perindopril 4 mg: n=57(32 males,25 females); mean age=51(15) years; baseline SBP/DBP not reported for all 57 patients;
Perindopril 8 mg: n=59(32 males,27 females); mean age=51(15) years; baseline SBP/DBP not reported for all 59 patients;
Perindopril 16 mg: n=57(35 males,22 females); mean age=51(15) years; baseline SBP/DBP not reported for all 57 patients;
Placebo: n=58(30 males,28 females); mean age=53(15) years; baseline SBP/DBP not reported for all 58 patients |
| Interventions |
Perindopril 2 mg once daily;
Perindopril 4 mg once daily;
Perindopril 8 mg once daily;
Perindopril 16 mg once daily;
Placebo;
administered in the morning |
| Outcomes |
Mean change from baseline in trough supine SBP/DBP using mercury sphygmomanometer;
Mean change from baseline in peak supine SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change reported, SD of change not reported, endpoint BP and SD not reported, baseline SEM reported, calculated baseline SD from N and baseline SEM, imputed baseline SBP SD for SBP SD of change; imputed overall trial mean DBP SD of change; BP data from Table 2, p. 1193; Jadad score=3; funding source= not reported |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
